Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD

Yonsei University

Status: Unknown

Conditions: Non-alcoholic Fatty Liver Disease; Type 2 Diabetes; Metabolic Syndrome

Treatments: Other: serum blood sampling

Study type: Observational

Funder types: Other

Identifiers

NCT02285218

4-2014-0073

Details and patient eligibility

About

To investigate the predictive roles of adipokines and hepatokines to detect non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia.

To examine the association or effects of clinical and biochemical factors (lab results and medication, etc.) on serum levels of adipokines and hepatokines in certain subjects with non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia.

Enrollment: 200 estimated patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. dyslipidemia 1. serum triglyceride≥150mg/dl, or taking medication to lower triglyceride levels (e.g. fibrates, niacin, omega-3, etc.) or 2. serum LDL-C≥100mg/dl, or taking medication to lower LDL-C levels (e.g. statin, ezetimibe, etc.)
2. type 2 diabetes 1. defined according to the ADA guideline (DM definition) or 2. taking any anti-diabetic medications
3. non-alcoholic fatty liver disease (NAFLD) 1. diagnosed as having fatty liver by ultrasonogram or 2. diagnosed as having fatty liver by transient elastogram (Fibroscan) or 3. diagnosed as having fatty liver by abdomina CT scan
4. Normal control 1. should not be included in other groups as above and 2. not taking any medication related to diabetes and dyslipidemia and 3. BMI <25kg/m2

Exclusion criteria

1. subjects who refused to agree with informed consents
2. subjects with organ-transplantation
3. serum creatinine ≥1.5mg/dl
4. pregnant women
5. liver cancer or pancreatic cancer
6. subjects with chronic hepatitis B or C virus infection
7. for NAFLD group, subjects with excessive alcohol consumption (men: ≥210g of alcohol per week, women: ≥140g of alcohol per week)

Trial design

200 participants in 4 patient groups

1) Normal control

Description:

metabolically healthy with no obesity

Treatment:

Other: serum blood sampling

2) dyslipidemia

Description:

high triglyceride levels or LDL-C levels

Treatment:

Other: serum blood sampling

3) type 2 diabetes

Description:

defined in 'inclusion criteria'

Treatment:

Other: serum blood sampling

4) non-alcoholic fatty liver disease

Description:

defined in 'inclusion criteria'

Treatment:

Other: serum blood sampling